drugset
drugset / Trial / NCT03466502

Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics

NCT03466502 ↗

Phase 4 Completed 104 enrolled University of Nevada, Reno Renown Regional Medical Center · collab
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.

Timeline

Start
2018-03-08
Primary completion
2022-02-17
Completion
2022-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Vancomycin Other / unclassified 125 mg Oral

Indications

Clostridium infectious disease